A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.


Updates from The Motley Fool

Latest updates on ArQule from Fool.com.
The Worst of 2012: ArQule

Losing a staggering 52.8% of its share price this year, pharmaceutical company ArQule is No. 6 on...

Making Cents in Penny Stocks

Low-priced stocks can be cheap for a good reason, but they might also present some great, overloo...



Stock Performance

View Interactive ARQL Charts
Sponsored by

Key Data Points

Primary metrics and data points about ArQule.
Current Price: $1.28
Prev Close: $1.20
Open: $1.26
Bid: $1.26
Ask: $1.27
Day's Range: $1.22 - $1.28
52wk Range: $1.13 - $2.17
Volume: 730,517
Avg Vol 240,719
Market Cap: $81M
P/E (ttm): -4.29
EPS (ttm): ($0.28)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about ArQule.
CAPS Rating 3 out of 5
 
170 Outperform
21 Underperform
CAPS All Stars
 
40 Outperform
6 Underperform

How do you think ArQule will perform against the market?



You pick for ArQule is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Paolo Pucci, CEO

26% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for ArQule.

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers